EP3397284A1 - Bilayer tablet formulations of montelukast and rupatadine - Google Patents

Bilayer tablet formulations of montelukast and rupatadine

Info

Publication number
EP3397284A1
EP3397284A1 EP17723019.0A EP17723019A EP3397284A1 EP 3397284 A1 EP3397284 A1 EP 3397284A1 EP 17723019 A EP17723019 A EP 17723019A EP 3397284 A1 EP3397284 A1 EP 3397284A1
Authority
EP
European Patent Office
Prior art keywords
layer
sodium
bilayer tablet
tablet formulation
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17723019.0A
Other languages
German (de)
French (fr)
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve AYHAN
Isil DEMIR
Gaye Ramazanoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3397284A1 publication Critical patent/EP3397284A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to a bilayer tablet formulation comprising montelukast sodium and rupatadine fumarate.
  • Montelukast sodium has one asymmetric center and is the R-isomer. A crystalline and an amorphous form are known. Montelukast sodium is a leukotriene receptor antagonist approved for the prophylaxis and chronic treatment of asthma.
  • the chemical name of montelukast is [R-(E)]-1 -[[[1 -[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1 -hydroxy-1 - methylethyl)-phenyl]propyl]thio]methyl] cyclopropane acetic acid mono sodium salt and has the structure shown in the following formula I. It works by blocking the action of substances in the body that cause the symptoms of asthma and allergic rhinitis. It is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma.
  • Rupatadine is a second generation antihistamine and PAF (Platelet-activating factor) antagonist used to treat allergies and is marketed under several trade names such as Rupafin, Alergoliber, Rinialer, Pafinur, Rupax and Ralif. Rupatadine fumarate has been approved for the treatment of allergic rhinitis and chronic urticaria in adults and children over 12 years.
  • the defined daily dose (DDD) is 10 mg orally.
  • rupatadine fumarate 8-Chloro-6,1 1 -dihydro-1 1 -[1 -[(5-methyl-3- pyridyl)methyl]-4-piperidylidene]-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine fumarate and has the structure shown in the following formula II.
  • Rupatadine fumarate Rupatadine is first disclosed in US6803468 (Ranbaxy Laboratories Limited) and there are several patent applications describing, its process and other salt forms.
  • capsule formulations including montelukast or rupatadine alone or may be in combination.
  • a capsule formulation is less effective than a tablet combination and this may cause compatibility and stability problems and moreover dissolution problems of active drug substances.
  • a bilayer tablet formulation has been provided to prevent the direct contact of active drug substances.
  • the main object of the present invention is to obtain a bilayer tablet formulation comprising a stable and compatible combination of montelukast sodium in first layer and rupatadine fumarate in second layer with a desired dissolution of active drug substances separately.
  • the present invention is aimed to obtain a bilayer tablet formulation to prevent an interaction of active drug substances, therefore the incompatibility problem of these agents is eliminated and efficient and desired dissolution and stability are obtained.
  • the bilayer tablet formulation of the present invention comprises 3.00 to 15.00 % by weight montelukast sodium as active drug substance in the first layer and comprises 5.00 to 20.00 % by weight rupatadine fumarate as active drug substance in the second layer.
  • the bilayer tablet formulation comprises at least one disintegrant.
  • the disintegrant is selected from the group comprising croscarmellose sodium, pregelatinized starch, crospovidone, sodium starch glycolate, low- substituted hydroxpropyl cellulose, polyvinylpyrrolidone (K - 30), hydroxylpropyl methyl cellulose, carboxy methyl cellulose calcium, sodium carboxy methyl cellulose, magnesium aluminum silica, sodium dodecyl sulphate, calcium silicate or mixtures thereof.
  • the disintegrant is croscarmellose sodium or pregelatinized starch or mixtures thereof.
  • the disintegrant is croscarmellose sodium in first layer and pregelatinized starch in second layer. Due to the use of different disintegrants separately in the layers, the efficient and desired dissolution of both active drug substances are achieved rapidly. Disintegrants give advantages to formulation in terms of binding strength to the layers. With the synergistic effect of disintegrants used in layers separately comprising active drug substances, layers adhere to each other and robust bilayer tablet with desired dissolution has been achieved. Disintegrants used in this present invention are croscarmellose sodium in first layer and pregelatinized starch in second layer.
  • the weight ratio (w/w) of croscarmellose sodium in first layer to pregelatinized starch in second layer is between 0.1 and 1 .0.
  • the weight ratio (w/w) is 0.5 - 0.7.
  • the bilayer tablet of the present invention further comprises at least one excipient.
  • the excipients are selected from the group comprising binders, fillers, lubricants and coloring agents or mixtures thereof.
  • Suitable binders may include but not limited to hydroxylpropyl cellulose (Klucel LF), hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sugars, glycose syrups, natural gums, guar gum, tragachanti gum, gelatins, pullulan, agar, alginate, sodium algynates, glycyrrhizin, polymetacrylates, collagen, alginate, sodium alginate, hyaluronic acid, pectin, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, cetostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage, polydextrose, polyethylene oxide, xylitol, sucrose stearate or mixtures thereof.
  • Suitable fillers may include, but not limited to microcrystalline cellulose (pH 101 , pH 102), lactose monohydrate, starch, mannitol, dibasic calcium phosphate, tribasic calcium di L t jp aanea y
  • the filler is microcrystalline cellulose (pH 101).
  • Suitable lubricants may include but not limited to magnesium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin or mixtures thereof.
  • the lubricant is magnesium stearate.
  • Suitable coloring agents may include but not limited to yellow iron oxide, Curcumin, Carmine, Indigo Carmine, Chlorophy II, Helindone pink CN, Diiodofluorescein or mixtures thereof.
  • the coloring agent is yellow iron oxide.
  • hydroxypropyl cellulose 1.00-5.00
  • microcrystalline cellulose (PH 101) 30.00-60.00
  • Montelukast Layer montelukast sodium, hydroxypropyl cellulose (Klucel LF), microcrystalline cellulose (PH 101 ), lactose monohydrate and half amount of croscarmellose sodium are taken into container. Powder mixture is spray-granulated with pure water. The mixture is dried. The rest of the croscarmellose sodium is added to this mixture, and mixed. Then, magnesium stearate is added to this mixture and mixed.
  • Rupatadine layer rupatadine fumarate, prejelatinized starch, microcrystalline cellulose (PH 101 ), lactose monohydrate and yellow iron oxide are taken into collete and powder mixture is wet granulated with pure water. Then, the mixture is sieved and dried in fluid-bed dryer. Then, the mixture is sieved again. Magnesium stareate is added and mixed again. Two powder mixtures, are put into tableting machine separately to form bilayer tablets.
  • Example 1 The bilayer tablet formulation of this present invention (Example 1 ), was tested by its dissolution profile in 0.5% solution of sodium dodecyl sulphate and at 37 ⁇ ⁇ using a USP apparatus II method in 900 ml_, rotating at 75 rpm against the reference product which is mentioned below as conventional (one layer) tablet or capsule form. The results are shown below in Table 1 .
  • Table 1 Dissolution profile test results (%)
  • Reference product* in one layer tablet or in capsule form: montelukast sodium , rupatadine fumarate, hydroxpropyl cellulose (Klucel LF), microcrystalline cellulose (pH101 ), lactose monohydrate, croscarmellose sodium and magnesium stearate.
  • the amount of the ingredients are same with the amounts given in example 1 , in montelukast layer
  • the dissolution and bioavailbilty of montelukast is significanti decreased.
  • they are formulated separately in a bilayer formulation the amounts are increased.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a bilayer tablet formulation comprising montelukast sodium and rupatadine fumarate.

Description

BILAYER TABLET FORMULATIONS OF MONTELUKAST AND RUPATADINE
Field of Invention
The present invention relates to a bilayer tablet formulation comprising montelukast sodium and rupatadine fumarate.
Background of Invention
Montelukast sodium has one asymmetric center and is the R-isomer. A crystalline and an amorphous form are known. Montelukast sodium is a leukotriene receptor antagonist approved for the prophylaxis and chronic treatment of asthma. The chemical name of montelukast is [R-(E)]-1 -[[[1 -[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1 -hydroxy-1 - methylethyl)-phenyl]propyl]thio]methyl] cyclopropane acetic acid mono sodium salt and has the structure shown in the following formula I. It works by blocking the action of substances in the body that cause the symptoms of asthma and allergic rhinitis. It is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma.
Formula I : Montelukast sodium
In patent W09716173, tablet formulation of montelukast sodium has been disclosed. It also exists in the market as tablet, chewable tablet and oral granule under the brand name of SINGULAIR® in U.S.
Rupatadine is a second generation antihistamine and PAF (Platelet-activating factor) antagonist used to treat allergies and is marketed under several trade names such as Rupafin, Alergoliber, Rinialer, Pafinur, Rupax and Ralif. Rupatadine fumarate has been approved for the treatment of allergic rhinitis and chronic urticaria in adults and children over 12 years. The defined daily dose (DDD) is 10 mg orally. The chemical name of rupatadine fumarate is 8-Chloro-6,1 1 -dihydro-1 1 -[1 -[(5-methyl-3- pyridyl)methyl]-4-piperidylidene]-5H-benzo[5,6]cyclohepta[1 ,2-b]pyridine fumarate and has the structure shown in the following formula II.
Formula II : Rupatadine fumarate Rupatadine is first disclosed in US6803468 (Ranbaxy Laboratories Limited) and there are several patent applications describing, its process and other salt forms.
In prior art, there may have some capsule formulations including montelukast or rupatadine alone or may be in combination. However, a capsule formulation is less effective than a tablet combination and this may cause compatibility and stability problems and moreover dissolution problems of active drug substances.
Thus, there is no combination of montelukast sodium with rupatadine fumarate especially in tablet form in prior art.
It has also been found that the combination of rupatadine and montelukast is more effective compared to rupatadine alone in the control of allergic rhinitis symptoms.
In addition, instead of one per se use, combining more than one molecule in one dosage form increases the patients' quality of life and patients' compliance. Considering all these, combinations of montelukast and rupatadine in a suitable pharmaceutical dosage formulation such as a bilayer tablet formulation is needed in the art. However, there are many challenges while combining two or more molecules in a tablet such as compatibility, dissolution and stability problems.
In this invention, to overcome these problems mentioned above, a bilayer tablet formulation of montelukast and rupatadine has been developed.
In further, in order to overcome stability and especially dissolution problems of active drug substances, a bilayer tablet formulation has been provided to prevent the direct contact of active drug substances.
Description of the invention
The main object of the present invention is to obtain a bilayer tablet formulation comprising a stable and compatible combination of montelukast sodium in first layer and rupatadine fumarate in second layer with a desired dissolution of active drug substances separately.
According to this embodiment, the present invention is aimed to obtain a bilayer tablet formulation to prevent an interaction of active drug substances, therefore the incompatibility problem of these agents is eliminated and efficient and desired dissolution and stability are obtained.
In order to combine two different molecules in one dosage form, molecules should be compatible with each other to achieve desired stability and dissolution for the patients' compliance. During the development study to combine montelukast and rupatadine, it has been found that montelukast shows stability and dissolution problems when it is used together with rupatadine in a conventional tablet formulation (one layer) or in capsule form. The analysis results that, the combination in conventional tablet or capsule form shows an increase in impurity and a decrease in dissolution of montelukast. Owing to the incompatibility problem of these active agents, in this invention bilayer tablet has been developed and desired dissolution and stability has been achieved. Dissolution results of the two active drug substances are given in below in Example 2, in more detail.
Thus, the bilayer tablet formulation of the present invention comprises 3.00 to 15.00 % by weight montelukast sodium as active drug substance in the first layer and comprises 5.00 to 20.00 % by weight rupatadine fumarate as active drug substance in the second layer.
In a further embodiment, the bilayer tablet formulation comprises at least one disintegrant. According to this embodiment, the disintegrant is selected from the group comprising croscarmellose sodium, pregelatinized starch, crospovidone, sodium starch glycolate, low- substituted hydroxpropyl cellulose, polyvinylpyrrolidone (K - 30), hydroxylpropyl methyl cellulose, carboxy methyl cellulose calcium, sodium carboxy methyl cellulose, magnesium aluminum silica, sodium dodecyl sulphate, calcium silicate or mixtures thereof. Preferably, the disintegrant is croscarmellose sodium or pregelatinized starch or mixtures thereof. More preferably, the disintegrant is croscarmellose sodium in first layer and pregelatinized starch in second layer. Due to the use of different disintegrants separately in the layers, the efficient and desired dissolution of both active drug substances are achieved rapidly. Disintegrants give advantages to formulation in terms of binding strength to the layers. With the synergistic effect of disintegrants used in layers separately comprising active drug substances, layers adhere to each other and robust bilayer tablet with desired dissolution has been achieved. Disintegrants used in this present invention are croscarmellose sodium in first layer and pregelatinized starch in second layer.
According to this embodiment, the weight ratio (w/w) of croscarmellose sodium in first layer to pregelatinized starch in second layer is between 0.1 and 1 .0. Preferably, the weight ratio (w/w) is 0.5 - 0.7.
In one embodiment, the bilayer tablet of the present invention further comprises at least one excipient. According to this embodiment, the excipients are selected from the group comprising binders, fillers, lubricants and coloring agents or mixtures thereof.
Suitable binders may include but not limited to hydroxylpropyl cellulose (Klucel LF), hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, sugars, glycose syrups, natural gums, guar gum, tragachanti gum, gelatins, pullulan, agar, alginate, sodium algynates, glycyrrhizin, polymetacrylates, collagen, alginate, sodium alginate, hyaluronic acid, pectin, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, cetostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage, polydextrose, polyethylene oxide, xylitol, sucrose stearate or mixtures thereof. Preferably the binder is hydroxylpropyl cellulose (Klucel LF).
Suitable fillers may include, but not limited to microcrystalline cellulose (pH 101 , pH 102), lactose monohydrate, starch, mannitol, dibasic calcium phosphate, tribasic calcium di Lt jpaaneay
phosphate, trehalose, isomalt, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof. Preferably the filler is microcrystalline cellulose (pH 101).
Suitable lubricants may include but not limited to magnesium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin or mixtures thereof. Preferably, the lubricant is magnesium stearate.
Suitable coloring agents, may include but not limited to yellow iron oxide, Curcumin, Carmine, Indigo Carmine, Chlorophy II, Helindone pink CN, Diiodofluorescein or mixtures thereof. Preferably, the coloring agent is yellow iron oxide.
Example 1 :
1st layer % by weight
montelukast sodium 3.00-15.00
hydroxypropyl cellulose (Klucel LF) 1.00-5.00
Φ
re
—I microcrystalline cellulose (PH 101) 30.00-60.00
</)
re lactose monohydrate 30.00-60.00
3
O croscarmellose sodium 1.00-5.00
C
O
Έ magnesium stearate 0.10-2.00
pure water 30.00-50.00
montelukast Layer 50.00 - 65.00
2"a layer % by weight
rupatadine fumarate 5.00-20.00
prejelatinized starch 2.00-10.00
0)
microcrystalline cellulose (PH 101) 30.00-60.00
lactose monohydrate 30.00-60.00
yellow iron oxide 0.10-2.00
DC magnesium stearate 0.10-2.00
pure water 40.00-60.00
rupatadine layer 35.00-50.00 The production of the formulation is carried out as follows:
Montelukast Layer: montelukast sodium, hydroxypropyl cellulose (Klucel LF), microcrystalline cellulose (PH 101 ), lactose monohydrate and half amount of croscarmellose sodium are taken into container. Powder mixture is spray-granulated with pure water. The mixture is dried. The rest of the croscarmellose sodium is added to this mixture, and mixed. Then, magnesium stearate is added to this mixture and mixed. Rupatadine layer: rupatadine fumarate, prejelatinized starch, microcrystalline cellulose (PH 101 ), lactose monohydrate and yellow iron oxide are taken into collete and powder mixture is wet granulated with pure water. Then, the mixture is sieved and dried in fluid-bed dryer. Then, the mixture is sieved again. Magnesium stareate is added and mixed again. Two powder mixtures, are put into tableting machine separately to form bilayer tablets.
Example 2 (Dissolution profile test)
The bilayer tablet formulation of this present invention (Example 1 ), was tested by its dissolution profile in 0.5% solution of sodium dodecyl sulphate and at 37 <Ό using a USP apparatus II method in 900 ml_, rotating at 75 rpm against the reference product which is mentioned below as conventional (one layer) tablet or capsule form. The results are shown below in Table 1 . Table 1 : Dissolution profile test results (%)
Reference product* (in one layer tablet or in capsule form): montelukast sodium , rupatadine fumarate, hydroxpropyl cellulose (Klucel LF), microcrystalline cellulose (pH101 ), lactose monohydrate, croscarmellose sodium and magnesium stearate. (The amount of the ingredients are same with the amounts given in example 1 , in montelukast layer) Therefore it is shown that, when these molecules are formulated together in one layer tablet form or in capsule form the dissolution and bioavailbilty of montelukast is significanti decreased. When they are formulated separately in a bilayer formulation the amounts are increased.

Claims

1 . A bilayer tablet formulation comprising montelukast sodium in first layer and rupatadine fumarate in second layer.
2. The bilayer tablet formulation according to claim 1 , wherein the first layer comprising 3.00 to 15.00 % by weight montelukast sodium as active drug substance and the second layer comprising 5.00 to 20.00 % by weight rupatadine fumarate as drug substance.
3. The bilayer tablet formulation according to claim 1 , further comprising at least one disintegrant.
4. The bilayer tablet formulation according to claim 3, wherein the disintegrant is selected from the group comprising croscarmellose sodium, pregelatinized starch, crospovidone, sodium starch glycolate, low-substituted hydroxpropyl cellulose, polyvinylpyrrolidone, hydroxylpropyl methyl cellulose, carboxy methyl cellulose calcium, sodium carboxy methyl cellulose, magnesium aluminum silica, sodium dodecyl sulphate, calcium silicate or mixtures thereof.
5. The bilayer tablet formulation according to claim 4, wherein the disintegrant is crosscarmellose sodium or pregelatinized starch or mixtures thereof.
6. The bilayer tablet formulation according to claim 5, wherein the disintegrant is crosscarmellose sodium in first layer and pregelatinized starch in second layer.
7. The bilayer tablet formulation according to claim 6, wherein the weight ratio (w/w) of croscarmellose sodium in first layer to pregelatinized starch in second layer is between 0.1 and 1 .0.
8. The bilayer tablet formulation according to any preceding claims, further comprising at least one excipient.
9. The bilayer tablet formulation according to claim 8, wherein the excipients are selected from the group comprising binders, fillers, lubricants and coloring agents or mixtures thereof.
10. The bilayer tablet formulation according to any preceding claims, comprising; a. 3.00 to 15.00 % of montelukast sodium
b. 1 .00 to 5.00 % of hydroxypropyl cellulose
c. 30.00 to 60.00 % of microcrystalline cellulose
d. 30.00 to 60.00 % of lactose monohydrate
e. 1 .00 to 5.00 % of croscarmellose sodium
f. 0.10 to 2.00 % of magnesium stearate
g. 30.00 to 50.00 % of pure water
in first layer and a. 5.00 to 20.00 % of rupatadine fumarate
b. 2.00 to 10.00 % of pregelatinized starch
h. 30.00 to 60.00 % of microcrystalline cellulose
i. 30.00 to 60.00 % of lactose monohydrate
j. 1 .00 to 5.00 % of croscarmellose sodium
k. 0.10 to 2.00 % of yellow iron oxide
I. 0.10 to 2.00 % of magnesium stearate
m. 40.00 to 60.00 % of pure water
in second layer.
EP17723019.0A 2016-04-22 2017-04-21 Bilayer tablet formulations of montelukast and rupatadine Pending EP3397284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201605261 2016-04-22
PCT/EP2017/059538 WO2017182641A1 (en) 2016-04-22 2017-04-21 Bilayer tablet formulations of montelukast and rupatadine

Publications (1)

Publication Number Publication Date
EP3397284A1 true EP3397284A1 (en) 2018-11-07

Family

ID=58701595

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17723019.0A Pending EP3397284A1 (en) 2016-04-22 2017-04-21 Bilayer tablet formulations of montelukast and rupatadine

Country Status (2)

Country Link
EP (1) EP3397284A1 (en)
WO (1) WO2017182641A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120379651A (en) 2022-12-15 2025-07-25 努科尔健康股份有限公司 Pharmaceutical composition comprising rupatadine and montelukast
KR20250081149A (en) * 2023-11-29 2025-06-05 알리코제약(주) Composition comprising montelukast and rupatadine with improved stability and manufacturing method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201410182A2 (en) * 2014-08-29 2016-03-21 Buelent Karaagac Pharmaceutical compositions containing leukotriene receptor antagonist and antihistaminic

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016173A1 (en) 1995-11-02 1997-05-09 Merck Frosst Canada Inc. New technology for wet granulation
US6803468B2 (en) 2000-08-29 2004-10-12 Ranbaxy Laboratories Limited Process for the synthesis of n-(5-methylnicontinoyl)-4 hydroxypiperidine, a key intermediate of rupatadine
WO2015069203A1 (en) * 2013-11-06 2015-05-14 Santa Farma Ilaç Sanayi A.Ş. Capsule comprising rupatadine fumarate and montelukast sodium

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201410182A2 (en) * 2014-08-29 2016-03-21 Buelent Karaagac Pharmaceutical compositions containing leukotriene receptor antagonist and antihistaminic

Also Published As

Publication number Publication date
WO2017182641A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
KR102006000B1 (en) Capsule formulation comprising montelukast or a pharmaceutically acceptable salt thereof, and levocetirizine or a pharmaceutically acceptable salt thereof
TWI565482B (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
JP6245677B2 (en) Orally disintegrating tablets
CN102223884B (en) Solid pharmaceutical composition
WO2012064301A2 (en) Physically improved tablet formulations
WO2011110939A2 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
DK3294719T3 (en) VORTIOXETIN-pyroglutamate
JP2018177815A (en) Escitalopram pharmaceutical composition
TW201106991A (en) Tablets
US20160008375A1 (en) Pharmaceutical formulations comprising quetiapine and escitalopram
EP3397284A1 (en) Bilayer tablet formulations of montelukast and rupatadine
CN102026626B (en) Granulate comprising escitalopram oxalate
JP2018530566A (en) 8-[(3R) -3-Amino-1-piperidinyl] -7- (2-butyn-1-yl) -3,7-dihydro-3-methyl-1- [4-methyl-2-quinazolinyl) methyl ] -1H-purine-2,6-dione or a pharmaceutical composition containing a pharmaceutically acceptable salt thereof
WO2017182644A1 (en) Tablet formulations of montelukast sodium and rupatadine fumarate
EP2949321A1 (en) Multilayer formulations of fexofenadine and montelukast
WO2019230937A1 (en) Solid oral dosage form having excellent dissolution properties
RU2677649C2 (en) Pharmaceutical compositions of montelucast and levocetirisine
JP6498158B2 (en) Orally disintegrating tablets
WO2013077829A1 (en) Water-soluble pharmaceutical granules
KR20210071242A (en) Pharmaceutical composition
BR102013004720B1 (en) STABLE PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION
JP6259043B2 (en) Sillostazol sustained-release tablets with improved dissolution rate and minimized side effects
TR201720395A2 (en) NEW TABLET FORMULATIONS OF MONTELUKAST SODIUM AND RUPATADINE FUMARATE
WO2019203746A2 (en) The pharmaceutical combination comprising raloxifene and aripiprazole

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

17P Request for examination filed

Effective date: 20180802

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190208

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET A.S.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN